Slide 1: Corporate Update March 2021
For personal use only Corporate Update March 2021 © Copyright Chimeric Therapeutics | Private and Confidential | March 2021
Slide 2: Disclaimer
Disclaimer For personal use only Certain statements contained in this presentation, including, without Given these uncertainties, undue reliance should not be placed on such limitation, statements containing the words “believes,” “plans,” forward-looking statements. The Company disclaims any obligat
Slide 3: Bringing the Promise of Cell Therapy to Life
At Chimeric we are focused on bringing the promise of cell therapy to life Bringing the for patients with cancer. For personal use only Promise of Cell Chimeric is a clinical stage cell therapy company which was founded on Therapy to Life promising Chlorotoxin (CLTX) CAR T technology from City of Ho
Slide 4: Cell Therapy Development
Cell Therapy Development For personal use only What is Cell Therapy? Cell therapy is the transfer of intact, live cells into a patient to help lessen or cure a disease. The global market for cell therapies is estimated to reach between USD $8-9 billion by 2026 Cell therapy is the most active sector
Slide 5: The Promise of Cell Therapy: Curative Potential in Cancer
The Promise of Cell Therapy: Curative Potential in Cancer For personal use only In oncology, cell therapy launched with the promise to be a therapeutic revolution as it demonstrated survival not previously seen with chemotherapies or immunotherapies. Today, data from CAR T trials in R/ R DLBCL has s
Slide 6: What is CAR T Cell Therapy?
What is CAR T Cell Therapy? Chimeric Antigen Receptor T (CAR T) Cell Therapy is a type of cell therapy that modifies a For personal use only patient’s own immune cells (T-cells) to use directly against their cancer. INSIDE THE BODY Cancer Antigen Target Cancer CAR T Cell Cell Chimeric Antigen Recept
Slide 7: Chlorotoxin (CLTX) CAR T First in Class
Chlorotoxin (CLTX) CAR T First in Class For personal use only In 2020, Chimeric Therapeutics licensed the exclusive global rights to the Chlorotoxin (CLTX) CAR T cell therapy developed at the City of Hope Cancer Centre. CLTX CAR T has a long life, composition of matter intellectual property profile
Slide 8: Unmet Medical Need in Glioblastoma
Unmet Medical Need in Glioblastoma For personal use only More than 300,000 patients globally are diagnosed each year with brain and nervous system cancer, and GBM is the most common and most lethal of these cancers ~8 months median overall survival for patients diagnosed with GBM ~38% of patients wi
Slide 9: Chlorotoxin (CLTX) CAR T: Potential Best in Class
Chlorotoxin (CLTX) CAR T: Potential Best in Class Due to the unique preclinical properties that CLTX CAR T has shown, it has the potential to address the high For personal use only unmet medical need for effective therapy against recurrent glioblastoma (WHO grade III-IV) Broad Recognition and Bindin
Slide 10: Phase 1 Clinical Study in Recurrent Glioblastoma
Phase 1 Clinical Study in Recurrent Glioblastoma Patient dosing commenced late September 2020 at City of Hope For personal use only Primary Objective: To assess the safety of CLTX CAR T cells for patients with MMP2 recurrent GBM and to determine the maximum tolerated dose schedule and a recommended
Slide 11: Phase 1 Update (as of March 18, 2021)
PHASE 1 CLTX CAR T Update (as of March 18, 2021) For personal use only Successful Completion of Planned Dosing in First Patient Cohort ICT and ICV Administration Total dose: 440 X 106 Chimeric Therapeutics, a clinical stage cell therapy company, is pleased to announce the successful completion of th
Slide 12: Preparing for Rapid Advancement to a Registration Trial
CLTX CAR T in Recurrent Glioblastoma Preparing for Rapid Advancement to a Registration Trial For personal use only A Phase 2 Single Arm Pivotal Trial to Evaluate CLTX Chimeric Antigen Receptor (CAR) T cells in Patients with Recurrent / Progressive GBM Phase 1 Recurrent PIVOTAL PHASE 2 Target Indicat
Slide 13: Expanding into Additional Tumour Types
CLTX CAR T Expanding into Additional Tumour Types For personal use only Based on evidence of CLTX binding in other solid tumours we are currently exploring initiation of a phase 1 basket trial in melanoma, colorectal cancer, prostate cancer , small cell lung cancer and sarcomas POTENTIAL INDICATIONS
Slide 14: Building the Chimeric Therapeutics Pipeline
Building the Chimeric Therapeutics Pipeline For personal use only Novel Allogeneic Alternative Chimeric is focused CAR Cell Cell Designs Sources Types on enhancing our pipeline with innovative cell therapies for oncology 14
Slide 15: Uniquely Positioned for Success in Cell Therapy Development
Uniquely Positioned for Success in Cell Therapy Development For personal use only We recognize that there are novel challenges in the development and commercialization of cell therapies that our experience makes us uniquely positioned to address Dr Syed Rizvi Dr Eliot Bourk Jennifer Chow Chief Medic
Slide 16: Chimeric Therapeutics Board of Directors
Chimeric Therapeutics Board of Directors For personal use only Paul Hopper Dr Lesley Russell Ms Leslie Chong Executive Chairman Ms Cindy Elkins Non-Executive Director Non-Executive Director Non-Executive Director Paul is the Founder of Chimeric and Ms. Russell has 25+ years of Ms Chong is currently
Slide 17: The Year Ahead 2021
The Year Ahead 2021 For personal use only Define manufacturing Phase 1 clinical trial Select contract research CLTX CAR T in GBM strategy for Phase 2 trial patient update organization for Phase 2 trial Q1 Q2 Q3 Q4 Develop phase 1 protocol for investigation of CLTX CAR T into other tumor types Explor
Slide 18: Bringing the Promise of Cell Therapy to Life
Bringing the Promise of For personal use only Cell Therapy to Life Inspired focus on developing cellular therapies to change the course of history for cancer patients Promising CLTX CAR T in phase 1 clinical trials in GBM with a fast to market registration path and potential in other diseases Expand
Slide 19: Getting to Know Cell Therapy
Getting to Know Cell Therapy For personal use only Allogeneic: The transfer of tissue or cells from one person to a distinct member of the same species. Antibodies: Proteins that help fight infections and toxins and are found in the blood. They are made by B lymphocytes. Each antibody binds to a spe
Slide 20: Contact
For personal use only Contact Jennifer Chow Chief Operating Officer jchow@chimerictherapeutics.com 908-723-8387